Key Speakers
Dr. Nabil G. Seidah
The implication of the proprotein convertases PCSK9 and PCSK7 in lipid metabolism:
is there a connection to cancer/metastasis?
Dr. Seidah obtained his BSc in 1969 from Cairo University in Egypt, and his PhD in 1973 from Georgetown University, USA. Since 1983, Dr. Seidah is the director of Laboratory of Biochemical Neuroendocrinology of IRCM. Dr Seidah is the recipient of several awards, including the Royal Society of Canada, the Order of Quebec and the Order of Canada. In 2011, he was awarded the Wilder Penfield prize for the best scientist in Quebec working in the biomedical field.
Professor Nima Rezaei
Inborn Errors of Immunity and Cancer: From Clinics to Genetics
Professor of Clinical Immunology at Tehran University of Medical Sciences, Vice Dean of Research in the School of Medicine and Head of Research Center for Immunodeficiencies. Nima Rezaei is the mastermind and the founder of the Universal Scientific Education and Research Network (USERN).
Dr. Reza Malekzadeh
Genetic basis of premature mortality, gastrointestinal and urinary bladder cancer in Iran
Former Minister of Health and Medical Education of Iran. Distinguished Professor of Medicine, Digestive Disease Research Institute. Tehran University of Medical Sciences. Dr. Malekzadeh has received many awards, including the Medal of Honor from International Agency for Research on cancer (IARC/WHO) for outstanding contribution in research on cancer (2018).
Dr. Marjan Yaghmaie
Clinical implications of molecular tumor profiling in metastatic breast cancer patients
Vice Chancellor in Research Affairs at Oncology, Hematology and Cell Therapy Research Institute. Associate Professor of Medical Genetics at Tehran University of Medical sciences. The representative of the science collaboration board of Iran with faculty members in USA &Canada at TUMS
Dr. Amineh Vaghefi
The Impact of percision oncology and the barriers to overcome
Dr. Amineh Vaghefi graduated with an MD degree from Tehran University of Medical Science in 2008, following which she completed her surgical and clinical pathology training at Iran University of Medical Science in 2012. In 2016, she joined the Sylvester Comprehensive Cancer Center at the University of Miami in Florida, where she studies on cancer genetics for two years. Her current focus is on precision oncology and hereditary cancer syndromes.
Dr. Mohammad Amin Moosavi
Autophagy in cancer: challenges and therapeutic opportunities
Associate professor of cancer biology and vice president for research at National Institute of Genetic Engineering and Biotechnology. Dr. Moosavi research works focus on cell death and stress response (ER stress & autophagy) mechanisms in cancer and related diseases.
DR. Seyed Mahdi Jafarnejad
Dysregulated mRNA Translation Initiation in Cancer
Mehdi received his PhD in Experimental Medicine from The University of British Columbia in 2012, investigating the mechanisms of dysregulated microRNA biogenesis in melanomas. This was followed by a postdoctoral training stint at Goodman Cancer Centre at McGill University, studying the mechanisms of post-transcriptional regulation of gene expression. He joined the Patrick Johnston Centre for Cancer Research at Queen’s University Belfast in 2019 as a Principal Investigator. His group currently focuses on mechanisms of regulation of mRNA translation and decay, alterations in these mechanisms in cancer, and how these mechanisms contribute to therapy-resistance in cancer.Conference in Iran in 2019.
Dr. Davood Bashash
The PI3K signaling axis and its implication in human malignancies
Dr. Bashash achieved his Ph.D. in hematology from Tehran University of Medical Science. Then he completed a fellowship in Clinical Laboratory Sciences at Iran University of Medical Science. He is also the research manager of the National Institute for Medical Research Development (NIMAD).
DR. Sina Salari
Curing cancer from within: the promise of cell therapy
Doctor Sina Salari completed his specialty training in Internal Medicine at Tehran University and completed his 3 years fellowship in Hematology and Oncology at Shahid Beheshti Medical University. Between 2013 to 2019 he was the Director of the deputy of treatment of the Oncology-Hematology and BMT department, and Head of the internal department and responsible authorized physician of Ayatollah Taleghani Hospital. Dr.Salari has a particular interest in cell therapy and treatment of gastrointestinal malignancies. He is a member of the Iranian Cancer-Immunotherapy scientific committee and organized the first cancer Immunotherapy Conference in Iran in 2019.
Dr. Yasser Riazalhosseini
Harnessing genomic data for precision medicine in renal cell carcinoma
Yasser Riazalhosseini undertook his doctoral and post-doctoral training at the German Cancer Research Centre (DKFZ) in Heidelberg, Germany. At DKFZ, he developed systems biology approaches that combine genomics datasets from hundreds of cancers coupled with detailed clinical data, and high-throughput functional studies. In 2012, Dr. Riazalhosseini joined the Department of Human Genetics at McGill, and was appointed Group Head of the Cancer Genomics program at the McGill Genome Centre. His group pioneered genomic characterization of renal cell carcinoma (RCC) through integrative analysis of genome and transcriptome sequencing data in the context of the International Cancer Genome Consortium (ICGC).
